Utilization of Intravenous (IV) Curcumin, Genistein, and Trastuzumab to Reduce HER2 receptors in Breast Cancer Patients

  • Shreya Bhandari Independence High School
  • Hasmitha Kamineni Independence High School
Keywords: breast cancer, HER2 receptors, tyrosine kinase inhibitors (TKIs), curcumin, genistein, trastuzumab (Herceptin), HER2-positive, HER2-negative


In recent decades, due to the increased growth, spread, and onset of cancer, interest has arisen in studying the methods that could be used to combat it. Breast cancer is the most prevalent form of cancer in the world. Due to the growing pervasiveness of this issue, a larger body of research is forming in the area of breast cancer with the intent to contain the spread of the potentially ravaging disease or diagnose it earlier. This research is intended to propose an alternative, possibly more efficient method to inhibit the chances of metastasis and continued prevalence of breast cancer in a patient. The related work discusses  similar research being done and builds on it to incorporate the novel method being proposed while explaining the components of the proposed treatment in question. The proposed method  aims to deplete HER2 protein receptors in breast cancer patients through the intravenous (IV) administration of the tyrosine kinase inhibitors (TKIs) curcumin and  genistein, as well as trastuzumab, which is more commonly known under the brand name Herceptin.  Depleting HER2 protein receptors can potentially cause the severity of HER2-positive breast cancer to decrease substantially, as well as reduce the probability of metastasis and recurrence, the rate of which is considerably  higher in HER2-positive cases when compared to that of  HER2-negative cases. The future work deals with alternate methods that could be explored with a similar intent as this research study and describes the potential implications of the study.


Download data is not yet available.

Author Biographies

Shreya Bhandari, Independence High School

Shreya Bhandari is a current junior in high school and will be graduating in May 2022. She is interested in pursuing a career in biology. She has completed her STEM endorsement and distinguished level of achievement endorsement, and is pursuing the multidisciplinary endorsement as well. In terms of academics, Shreya has always excelled. In addition to her numerous AP courses, including AP Biology, AP Environmental Science, and AP Physics, she is a National AP Scholar with Honor, is a top student in her class, and is still awaiting to hear the results of the national merit scholarship award. All these accomplishments not only represent Shreya’s intelligent nature, but more importantly emphasize how much of a hard worker she is. Shreya is very active in her school and community. Shreya is in Health Occupations Students of America (a medical society), Key Club (an organization aimed at volunteering for the better of society), and National Honors Society. Through these clubs, Shreya is able to be with like-minded individuals and create a network of people for herself. She is the president and founder of Future Problem Solving (FPS), a club focused on generating and implementing solutions to problems that may arise in the future. The club, with about 50 members, has instilled values such as leadership, service, and character in Shreya. She has conducted research on breast cancer, ErBb2 oncogene, the MRSA infection, synergistic therapies, and numerous other areas. She has won numerous accolades such as the City of Allen Sophomore of the Year Award, the NCWIT Rising Star award, FPS State Winner award, etc. In the future, she hopes to have a positive impact on society through her extensive biological knowledge and commitment to better society.


Hasmitha Kamineni, Independence High School

Hasmitha Kamineni is a 11th grader at Independence High School in Frisco, Texas who will be graduating in May 2022 and is interested in pursuing a career in the field of biology. She has completed her STEM and multidisciplinary endorsements, and has achieved the Distinguished Level of Achievement status. She has taken challenging AP courses, including AP Biology, AP Psychology, AP Physics I and other various AP classes in order to demonstrate her willingness to persevere academic excellence. Moreover, Hasmitha is an active member of her school, as she is a part of Mu Alpha Theta, which is a math honors club, Health Occupations Students of America, which is a club for students interested in health science, Science Olympiad, National Honor Society, and Future Problem Solving Program International Frisco. She will serve as the historian of Science Olympiad and the Secretary of FPSPI in the upcoming school year. Additionally, her accolades include that she is a Commended Scholar, has participated in the Pathophysiology competition at the HOSA State Competition due to placing 3rd in the Area Competition, and has placed 3rd with her team at the FPSPI State Bowl. Furthermore, she is in the top 10% of her class. Hasmitha has thoroughly researched breast cancer, especially the role of the ERBB2 oncogene, which encodes HER2 receptors, an excess of which can lead to a greater chance of metastasis and a graver prognosis. Additionally, she has proposed, through extensive research, a synergistic therapy to effectively treat critical MRSA infections. She will continue researching various diseases and associated causes to find potential treatments in order to make the world a better place, one step at a time.


Metibemu, Samuel. “Exploring Receptor Tyrosine Kinases-Inhibitors in Cancer Treatments.” Egyptian Journal of Medical Human Genetics, 23 Dec. 2019, jmhg.springeropen.com/articles/10.1186/s43042-019-0035-0.

Sakla, Mary S et al. “Genistein Affects HER2 Protein Concentration, Activation, and Promoter Regulation in BT-474 Human Breast Cancer Cells.” Endocrine vol. 32,1 (2007): 69-78. doi:10.1007/s12020-007-9006-1

NHS website. “Herceptin (Trastuzumab).” Nhs.Uk, 21 Nov. 2019, www.nhs.uk/conditions/herceptin..

“Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications.” PubMed Central (PMC), 2014, www.ncbi.nlm.nih.gov/pmc/articles/PMC4170925.

Lai, Hung-Wen. “The Potential Utility of Curcumin in the Treatment of HER-2-Overexpressed Breast Cancer: An In Vitro and In Vivo Comparison Study with Herceptin.” PubMed, 2012, pubmed.ncbi.nlm.nih.gov/21876713.

Vutakuri, Neha. “Curcumin- Breast Cancer Therapeutic Agent to Replace Allopathic Treatments with Extensive Side Effects.” Journal of Young Investigators 35 (2018): n.

Abbaspour, H., and A. Safipour Afshar. “Curcumin Inhibits the Expression of Ornithine Decarboxylase and Adenosine Deaminase Genes in MCF-7 Human Breast Cancer Cells”. Archives of Biological Sciences, vol. 70, no. 4, Dec. 2018, pp. 639-45, https://www.serbiosoc.org.rs/arch/index.php/abs/article/view/2642.

Jaiswal AS, Marlow BP, Gupta N, Narayan S. Beta-catenin-mediated Transactivation and Cell-cell Adhesion Pathways are Important in Curcumin (diferuloylmethane)-Induced Growth Arrest and Apoptosis in Colon Cancer Cells. Oncogene. 2002;21:8414–8427. doi: 10.1038/sj.onc.1205947.

Fan, Panhong. “Genistein Decreases the Breast Cancer Stem-like Cell Population Through Hedgehog Pathway.” Stem Cell Research & Therapy, 11 Dec. 2013, stemcellres.biomedcentral.com/articles/10.1186/scrt357.

Venkiteswaran, Sripriya. “Curcumin Inhibits the Growth of HER-2 Overexpressing Human Breast Cancer Cells by Interference with the Glutathione Pathway.” Cancer Research, 1 May 2007, cancerres.aacrjournals.org/content/67/9_Supplement/3467.

Nagaraju, Ganji Purnachandra, et al. “Impact of Curcumin on Breast Cancer.” OUP Academic, Oxford University Press, 6 July 2012, academic.oup.com/ib/article-abstract/4/9/996/5204473.

Gajria, Devika, and Sarat Chandarlapaty. “HER2-Amplified Breast Cancer: Mechanisms of Trastuzumab Resistance and Novel Targeted Therapies.” Expert Review of Anticancer Therapy, U.S. National Library of Medicine, Feb. 2011, www.ncbi.nlm.nih.gov/pmc/articles/PMC3092522/.

Wang, Yiwei et al. “Curcumin in Treating Breast Cancer: A Review.” Journal of Laboratory Automation vol. 21,6 (2016): 723-731. doi:10.1177/2211068216655524

How to Cite
Bhandari, S., & Kamineni, H. (2021). Utilization of Intravenous (IV) Curcumin, Genistein, and Trastuzumab to Reduce HER2 receptors in Breast Cancer Patients. International Journal for Research in Applied Sciences and Biotechnology, 8(4), 104-109. https://doi.org/10.31033/ijrasb.8.4.16